MCU and atherosclerosis: In the present study, it will be observed if rosuvastatin could inhibit Ang II and the Pyk2/MCU pathway simultaneously in the development process of atherosclerosis, which would further identify the Pyk2/MCU pathway as a new target to prevent EC dysfunction and AS progression as well as Ang II related to Pyk2/MCU at some levels.